Genscript Biotech Corporation 1548
HKEX · Hong Kong SAR China · Health Technology
HKD 44.86+3.46 (+8.36%)
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · HKD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Demand for biologics, targeted therapies and personalized medicine is rising, while AI-led protein design and scalable bioprocessing unlock new opportunities.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Recombinant Proteins Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global recombinant proteins market was valued at US$3.3 billion in 2024 and is projected to reach US$5.8 billion by 2030, expanding at a compound annual growth rate of 10.2%. Ma
Capitalize on gene therapy and vaccine demand through automated, scalable DNA synthesis and actionable segment, regional, and competitive insights.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "DNA Manufacturing Market Size, Share & Trends Analysis Report by Type, Grade, Application, End Use, Region, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering. The global DNA manufacturing market was valued at an estimated USD 6.4 billion in 2025 and is projected to reach US
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.